All Clinical Trials

The OUtMATCH Study

Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Children and Adults

  • ClinicalTrials.gov ID: NCT03881696
  • Recruiting participants (Starts Jul. 31, 2019)
  • Not accepting healthy volunteers
  • UTSW Principal Investigator: JOHN ANDREW BIRD

summary

Our researchers are trying to determine if a study medication called omalizumab alone or combined with oral immunotherapy may help people with multiple food allergies. Participants must have a peanut allergy and at least two other food allergies to milk, egg, wheat, cashew, hazelnut, or walnut.


Enrollment
: This trial is active and currently enrolling.

How to Participate: For more information, call 214-456-1438 or email foodallergyresearch@childrens.com

Who Can Participate: Anyone between the ages of 1-55 years who has a peanut allergy and at least two other food allergies to milk, egg, wheat, cashew, hazelnut or walnut.

Age Range: 1-55 years

Gender: Any

Estimated Time Commitment (# of visits, etc.): This is a multi-stage study, with an individual study participation of up to 4 years and 8 months, but not past December 2023.

Study Location: Children’s Medical Center, Dallas

Compensation: Provided

Study Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Site Principal Investigator: J. Andrew Bird, MD

Study Coordinator: Amy Arneson, RN

Study Primary Investigator: Robert Wood, MD

For more information, please contact: foodallergyresearch@childrens.com

objective

The primary objective is to compare the ability to consume foods without dose-limiting symptoms during a double-blind placebo-controlled food challenge (DBPCFC) after treatment with either omalizumab or placebo for omalizumab.

If you are interested in this clinical trial, please contact Amy Arneson on the Children’s Health Research Team.Call 214-456-1438Email